The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Open accessPublished version of a preprint
Abstract
Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the MSI that often leads to cancer simultaneously makes the inhibition of Werner syndrome ATP-dependent helicase (WRN) lethal to the tumor cells62,63”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [62]
In the citing paper
“''Fitness Scores'' that were calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines and represent a quantitative measure of the reduction of cell viability elicited by a gene inactivation via CRISPR/Cas9 (https://score.depmap.sanger.ac.uk) (Behan et al., 2019;van der Meer et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Behan et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Most patients however do not benefit from such targeted therapies in part due to limited knowledge of candidate targets(Zehir et al. 2017).”
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Cited by
Sorted by citations
Items 301–400 of 999
Hydroxysteroid (17β) dehydrogenase 12 is essential for metabolic homeostasis in adult mice
Heikelä, H., Ruohonen, S. T., Adam, M., Viitanen, R., Liljenbäck, H., Eskola, O., Gabriel, M., Mairinoja, L., Pessia, A., Velagapudi, V., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00042.2020 · Cited by 34
Nie, M., Du, L., Ren, W., Joung, J., Ye, X., Shi, X., Ciftci, S., Liu, D., Wu, K., Zhang, F., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03695-8 · Cited by 35
Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
Orben, F., Lankes, K., Schneeweis, C., Hassan, Z., Jakubowsky, H., Krauß, L., Boniolo, F., Schneider, C., Schäfer, A., Murr, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.151353 · Cited by 36
Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers
Marjon, K., Kalev, P., & Marks, K. M. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033444 · Cited by 32
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
Self-citationAn Overview of Candidate Therapeutic Target Genes in Ovarian Cancer
Alexandrova, E., Pecoraro, G., Sellitto, A., Melone, V., Ferravante, C., Rocco, T., Guacci, A., Giurato, G., Nassa, G., Rizzo, F. M., et al. (2020) · Cancers · doi:10.3390/cancers12061470 · Cited by 32
CRISPR screen in cancer: status quo and future perspectives.
He, C., Han, S., Chang, Y., Wu, M., Zhao, Y., Chen, C. Y., & Chu, X. (2021) · PubMed · Cited by 37
Lenoir, W. F., Morgado, M. C., DeWeirdt, P. C., McLaughlin, M. E., Griffith, A. L., Sangree, A. K., Feeley, M. N., Anvar, N. E., Kim, E., Bertolet, L. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26867-8 · Cited by 31
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency datasetsPreprint
Dempster, J. M., Pacini, C., Pantel, S., Behan, F. M., Green, T., Krill-Burger, J. M., Beaver, C., Younger, S. T., Zhivich, V., Najgebauer, H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/604447 · Cited by 32
Self-citationGene expression has more power for predicting in vitro cancer cell vulnerabilities than genomicsPreprint
Dempster, J. M., Krill-Burger, J. M., McFarland, J. M., Warren, A. C., Boehm, J. S., Vázquez, F., Hahn, W. C., Golub, T. R., & Tsherniak, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.21.959627 · Cited by 31
Hagel, K. R., Arafeh, R., Gang, S., Arnoff, T. E., Larson, R. C., Doench, J. G., Mathewson, N. D., Wucherpfennig, K. W., Maus, M. V., & Hahn, W. C. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2245 · Cited by 34
RNA-modifying enzymes and their function in a chromatin context
Tzelepis, K., Rausch, O., & Kouzarides, T. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0312-0 · Cited by 32
The WRN helicase: resolving a new target in microsatellite unstable cancers
van Wietmarschen, N., Nathan, W. J., & Nussenzweig, A. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2021.06.014 · Cited by 32
High-throughput methods for genome editing: the more the better
Huang, Y., Shang, M., Liu, T., & Wang, K. (2022) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiac017 · Cited by 32
Targeting SHP2 phosphatase in hematological malignancies
Kanumuri, R., Pasupuleti, S. K., Burns, S. S., Ramdas, B., & Kapur, R. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066518 · Cited by 31
Computational estimation of quality and clinical relevance of cancer cell lines
Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31
Self-citationHarman, J. R., Thorne, R., Jamilly, M., Tapia, M. C., Crump, N. T., Rice, S., Beveridge, R. D. D., Morrissey, E. R., Bruijn, M. F. T. R. D., Roberts, I. A. G., et al. (2021) · Genome Research · doi:10.1101/gr.268490.120 · Cited by 30
Li, Y., Zeng, M., Zhang, F., Wu, F., & Li, M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac779 · Cited by 30
HAPSTR1 localizes HUWE1 to the nucleus to limit stress signaling pathways
Monda, J. K., Ge, X., Hunkeler, M., Donovan, K. A., Ma, M. W., Jin, C. Y., Leonard, M., Fischer, E. S., & Bennett, E. J. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112496 · Cited by 35
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Elurbide, J., Colyn, L., Latasa, M. U., Uriarte, I., Mariani, S., López-Pascual, A., Valbuena-Goiricelaya, E., Castelló-Uribe, B., Arnes‐Benito, R., Adán-Villaescusa, E., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332998 · Cited by 32
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · Pharmaceuticals · doi:10.3390/ph18050607 · Cited by 37
Ercolano, G., Cicco, P. D., Rubino, V., Terrazzano, G., Ruggiero, G., Carriero, R., Kunderfranco, P., & Ianaro, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01456 · Cited by 31
Synthetic Lethal Interactions of RECQ Helicases
Datta, A., Dhar, S., Awate, S., & Brosh, R. M. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.09.001 · Cited by 31
van Harten, A. M., & Brakenhoff, R. H. (2021) · Cancers · doi:10.3390/cancers13112774 · Cited by 33
Mini-batch optimization enables training of ODE models on large-scale datasets
Stapor, P. L., Schmiester, L., Wierling, C., Merkt, S., Pathirana, D., Lange, B. M. H., Weindl, D., & Hasenauer, J. (2022) · Nature Communications · doi:10.1038/s41467-021-27374-6 · Cited by 31
Shi, X., Gao, X., LIU, W., Tang, X., LIU, J., Pan, D., Duan, X., JIN, Y., Ren, W., Yang, L., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028964 · Cited by 29
Uncovering an allosteric mode of action for a selective inhibitor of human Bloom syndrome protein
Chen, X., Ali, Y. I., Fisher, C. E., Arribas-Bosacoma, R., Rajasekaran, M. B., Williams, G., Walker, S., Booth, J. R., Hudson, J. J., Roe, S. M., et al. (2021) · eLife · doi:10.7554/elife.65339 · Cited by 34
Zhao, W., Chen, K.-F., Liu, M., Jia, X., Huang, Y., Hao, B., Hu, H., Shen, X., Yu, Q., & Tan, M. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01072-z · Cited by 29
Liang, Y., Luo, H., Lin, Y., & Gao, F. (2024) · iMeta · doi:10.1002/imt2.157 · Cited by 29
Challenges for the Discovery of Non‐Covalent WRN Helicase Inhibitors
Heuser, A., Abdulrahman, W., Bechter, E., Blank, J., Buhr, S., Erdmann, D., Fontana, P., Mermet‐Meillon, F., Meyerhofer, M., Strang, R. S., et al. (2024) · ChemMedChem · doi:10.1002/cmdc.202300613 · Cited by 29
TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP), A Novel Therapeutic Target Of Breast Cancer
Cheng, L., Li, Z., Huang, Y., Zhang, X., Dai, X., Shi, L., Xi, P.-W., Wei, J., & Ding, Q. (2019) · Cancer Management and Research · doi:10.2147/cmar.s219289 · Cited by 29
Kolmus, K., Erdenebat, P., Stewig, B. E., Szymańska, E., Goryca, K., Derezińska‐Wołek, E., Szumera‐Ciećkiewicz, A., Brewińska‐Olchowik, M., Piwocka, K., Prochorec‐Sobieszek, M., et al. (2021) · Journal of Cell Science · doi:10.1242/jcs.250951 · Cited by 28
Ding, R., Long, J., Yuan, M., Jin, Y., Yang, H., Chen, M., Chen, S., & Duan, G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.639108 · Cited by 32
Unraveling cancer lineage drivers in squamous cell carcinomas
Guan, Y., Wang, G., Fails, D. M., Nagarajan, P., & Ge, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107448 · Cited by 30
Richardson, T. E., Walker, J. M., Hambardzumyan, D., Brem, S. S., Hatanpaa, K. J., Viapiano, M. S., Pai, B., Umphlett, M., Becher, O. J., Snuderl, M., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02761-7 · Cited by 28
CRISPR Diagnosis and Therapeutics with Single Base Pair Precision
Lee, S. H., Park, Y., Jin, Y. B., Kim, S., & Hur, J. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.008 · Cited by 29
Ross‐Thriepland, D., Bornot, A., Butler, L., Desai, A. S., Jaiswal, H., Peel, S. E., Hunter, M. R., Odunze, U., Isherwood, B. J., & Gianni, D. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220925770 · Cited by 26
Zhang, C., Lu, X., Huang, J., He, H., Chen, L., Liu, Y., Wang, H., Xu, Y., Xing, S., Ruan, X., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.328 · Cited by 28
Cancer synthetic vulnerabilities to protein arginine methyltransferase inhibitors
Guccione, E., Schwarz, M. C., Tullio, F. D., & Mzoughi, S. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.004 · Cited by 28
Farheen, J., Hosmane, N. S., Zhao, R., Zhao, Q. D., Iqbal, M. Z., & Kong, X. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100450 · Cited by 29
Clinical prospects of WRN inhibition as a treatment for MSI tumours
Morales-Juarez, D. A., & Jackson, S. P. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00319-y · Cited by 27
Synthetic lethal gene pairs: Experimental approaches and predictive models
Tang, S., Gökbağ, B., Fan, K., Shao, S., Huo, Y., Wu, X., Cheng, L., & Li, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.961611 · Cited by 28
RECQ DNA Helicases and Osteosarcoma
Lu, L., Jin, W., & Wang, L. L. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_3 · Cited by 28
The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
Ge, M., Luo, J., Wu, Y., Shen, G., & Kuang, X. (2024) · MedComm – Oncology · doi:10.1002/mog2.70 · Cited by 31
Rhein Derivative 4F Inhibits the Malignant Phenotype of Breast Cancer by Downregulating Rac1 Protein
Li, X., Liu, Y., Zhao, Y., Tian, W., Zhai, L., Pang, H., Kang, J., Hou, H., Chen, Y., & Li, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00754 · Cited by 27
The Cancer Dependency Map enables drug mechanism‐of‐action investigations
Vázquez, F., & Boehm, J. S. (2020) · Molecular Systems Biology · doi:10.15252/msb.20209757 · Cited by 27
Prime, S. S., Cirillo, N., Cheong, S. C., Prime, M. S., & Parkinson, E. K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.025 · Cited by 29
Li, F., Li, J., Yu, J., Pan, T., Yu, B., Sang, Q., Dai, W., Hou, J., Yan, C., Zang, M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103436 · Cited by 27
Understanding the DNA double-strand break repair and its therapeutic implications
Ray, U., & Raghavan, S. C. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103177 · Cited by 27
Therapeutic Potential of EWSR1–FLI1 Inactivation by CRISPR/Cas9 in Ewing Sarcoma
Cervera, S. T., Rodriguez‐Martin, C., Fernández-Tabanera, E., de Mera, R. M. M.-F., Morin, M., Fernández-Peñalver, S., Iranzo-Martínez, M., Amhih-Cardenas, J., García‐García, L., González‐González, L., et al. (2021) · Cancers · doi:10.3390/cancers13153783 · Cited by 29
Vinceti, A., Karakoç, E., Pacini, C., Perron, U., Lucia, R. R. D., Garnett, M. J., & Iorio, F. (2021) · BMC Genomics · doi:10.1186/s12864-021-08129-5 · Cited by 27
Self-citationCai, W., Nguyen, M. Q., Wilski, N. A., Purwin, T. J., Vernon, M., Tiago, M., & Aplin, A. E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3217 · Cited by 27
Lalonde, M., Sasseville, M., Gélinas, A.-M., Milanese, J., Béland, K., Drouin, S., Haddad, É., & Marcotte, R. (2022) · Haematologica · doi:10.3324/haematol.2022.280786 · Cited by 28
CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
Gautron, A., Bachelot, L., Aubry, M., Leclerc, D., Quéméner, A. M., Corre, S., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013466 · Cited by 32
Belhocine, M., Simonin, M., Flores, J. D. A., Cieślak, A., Manosalva, I., Pradel, L. C., Smith, C. L., Mathieu, È.-L., Charbonnier, G., Martens, J. H. A., et al. (2021) · Genome Research · doi:10.1101/gr.266924.120 · Cited by 27
C16orf72/HAPSTR1 is a molecular rheostat in an integrated network of stress response pathways
Amici, D. R., Ansel, D. J., Metz, K. A., Smith, R. S., Phoumyvong, C. M., Gayatri, S., Chamera, T., Edwards, S. L., O’Hara, B. P., Srivastava, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111262119 · Cited by 29
Tedeschi, A., Schischlik, F., Rocchetti, F., Popow, J., Ebner, F., Gerlach, D., Geyer, A., Santoro, V., Boghossian, A. S., Rees, M. G., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0386 · Cited by 28
He, Y., Tu, X., Xue, Y., Chen, Y., Ye, B., Li, X., Li, D., Zhong, Z., & Zhong, Q. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101357 · Cited by 31
Liu, T., Yang, D., Wei, Q., Wang, Y., Tian, L., Liu, X., Yang, Y., Luo, Q.-Y., Xu, J., Liu, Y., et al. (2025) · Molecules and Cells · doi:10.1016/j.molcel.2025.05.015 · Cited by 27
Kang, C.-M., Bai, H.-L., Li, X.-H., Huang, R.-Y., Zhao, J.-J., Dai, X.-Y., Zheng, L., Qiu, Y.-R., Hu, Y.-W., & Wang, Q. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.002 · Cited by 26
Kondo, T. (2020) · Cancer Science · doi:10.1111/cas.14669 · Cited by 28
CEN‐tools: an integrative platform to identify the contexts of essential genes
Sharma, S., Dinçer, C., Weidemüller, P., Wright, G. J., & Petsalaki, E. (2020) · Molecular Systems Biology · doi:10.15252/msb.20209698 · Cited by 25
Identification of transcription factor co-regulators that drive prostate cancer progression
Manjunath, S., Wani, S. A., Long, M. D., Leach, D. A., Mathé, E. A., Bevan, C. L., & Campbell, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-77055-5 · Cited by 26
A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective
Kwon, J. J., & Hahn, W. C. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00627-20 · Cited by 26
Advancing drug discovery using the power of the human genome
Heilbron, K., Mozaffari, S. V., Vacic, V., Yue, P., Wang, W., Shi, J., Jubb, A. M., Pitts, S. J., & Wang, X. (2021) · The Journal of Pathology · doi:10.1002/path.5664 · Cited by 25
Zhou, Z., Li, Y., Ma, X., Cao, B., Peng, T., Sheng, Y., Peng, H., Li, R., Cao, Y., Xi, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00018 · Cited by 27
Co‐occurrence of BAP1 and SF3B1 mutations in uveal melanoma induces cellular senescence
Yu, L., Zhou, D., Zhang, G., Ren, Z., Luo, X., Liu, P., Plouffe, S. W., Meng, Z., Moroishi, T., Li, Y., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13128 · Cited by 26
ITGInsight–discovering and visualizing research fronts in the scientific literature
Wang, X., Zhang, S., & Liu, Y. (2021) · Scientometrics · doi:10.1007/s11192-021-04190-9 · Cited by 26
Salvati, A., Melone, V., Sellitto, A., Rizzo, F. M., Tarallo, R., Nyman, T. A., Giurato, G., Nassa, G., & Weisz, A. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01547-7 · Cited by 25
CRISPR/Cas‐Based MicroRNA Biosensors
Zhang, Q., Zhang, X., Zou, X., Ma, F., & Zhang, C. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202203412 · Cited by 26
Pooled Genome-Scale CRISPR Screens in Single Cells
Schraivogel, D., Steinmetz, L. M., & Parts, L. (2023) · Annual Review of Genetics · doi:10.1146/annurev-genet-072920-013842 · Cited by 28
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy DevelopmentPreprint
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors
Thomas, K. L., Bouguenina, H., Miller, D. S. J., Sialana, F. J., Hayhow, T. G., Choudhary, J. S., Rossanese, O. W., & Bellenie, B. R. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00616 · Cited by 25
Bhansali, D., Tu, N. H., Inoue, K., Teng, S. L., Li, T., Tran, H. D., Kim, D., Dong, J., Peach, C. J., Sokrat, B., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122874 · Cited by 25
Analysis of CRISPR‐Cas9 screens identifies genetic dependencies in melanoma
Christodoulou, E., Rashid, M., Pacini, C., Droop, A., Robertson, H., van Groningen, T., Teunisse, A. F. A. S., Iorio, F., Jochemsen, A. G., Adams, D. J., et al. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12919 · Cited by 26
Self-citationKEAP1 Mutations Drive Tumorigenesis by Suppressing SOX9 Ubiquitination and Degradation
Shao, N., Huang, H., Idris, M., Xu, P., Xu, F., Dong, S., & Liu, C. (2020) · Advanced Science · doi:10.1002/advs.202001018 · Cited by 24
Armanetti, P., Chillà, A., Margheri, F., Biagioni, A., Menichetti, L., Margheri, G., Ratto, F., Centi, S., Bianchini, F., Severi, M., et al. (2020) · Advanced Science · doi:10.1002/advs.202001175 · Cited by 25
Ding, B., Liu, Y., Liu, Z., Zheng, L., Xu, P., Zhao, C., Wu, P., Zhao, Y., Pan, Q., Guo, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi6020 · Cited by 22
RETRACTED: CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment
Akram, F., Haq, I. U., Sahreen, S., Nasir, N., Naseem, W., Imitaz, M., & Aqeel, A. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221132078 · Cited by 25
RetractedChang, X., Tamauchi, S., Yoshida, K., Yoshihara, M., Yokoi, A., Shimizu, Y., Ikeda, Y., Yoshikawa, N., Kiyono, T., Yamamoto, Y., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.04.003 · Cited by 25
Mori, M., Kubota, Y., Durmaz, A., Gurnari, C., Goodings, C., Ademà, V., Ponvilawan, B., Bahaj, W., Kewan, T. Z., LaFramboise, T., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02003-x · Cited by 25
Ontology-based prediction of cancer driver genes
Althubaiti, S., Karwath, A., Dallol, A., Noor, A., Alkhayyat, S. S., Al‐Wassia, R., Mineta, K., Gojobori, T., Beggs, A. D., Schofield, P. N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53454-1 · Cited by 23
The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter
Gollavilli, P. N., Parma, B., Siddiqui, A., Yang, H., Ramesh, V., Napoli, F., Schwab, A., Natesan, R., Mielenz, D., Asangani, I. A., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01708-6 · Cited by 24
CRISP-view: a database of functional genetic screens spanning multiple phenotypes
Cui, Y., Cheng, X., Chen, Q., Song, B., Chiu, A., Gao, Y., Dawson, T., Chao, L., Zhang, W., Li, D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa809 · Cited by 24
A review of the known MTA-cooperative PRMT5 inhibitors
Hu, M. L., & Chen, X. (2024) · RSC Advances · doi:10.1039/d4ra05497k · Cited by 27
SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO
Borck, P. C., Boyle, I., Janković, K., Bick, N. R., Foster, K. J., Lau, A. C., Parker-Burns, L., Lubicki, D. A., Li, T., Borah, A. A., et al. (2025) · Nature · doi:10.1038/s41586-024-08509-3 · Cited by 25
A combined enteric neuron-gastric tumor organoid reveals metabolic vulnerabilities in gastric cancer
Chan, B. K. C., Zhang, C., Poon, C. H., Lee, M. H. Y., Chu, H. Y., Wang, B., Chen, S.-G., Yan, H. H. N., Leung, S. Y., & Wong, A. S. L. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.08.006 · Cited by 25
WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype
Zimmer, K., Puccini, A., Xiu, J., Baca, Y., Spizzo, G., Lenz, H., Battaglin, F., Goldberg, R. M., Grothey, A. F., Shields, A. F., et al. (2020) · Cancers · doi:10.3390/cancers12051319 · Cited by 24
Recent advances in amino acid-metal coordinated nanomaterials for biomedical applications
Wang, S., Zhao, Y., Zhang, Z., Zhang, Y., & Li, L. (2021) · Chinese Journal of Chemical Engineering · doi:10.1016/j.cjche.2021.03.013 · Cited by 22
Lee, D.-H., Kang, S.-H., Choi, D., Ko, M., Choi, E., Ahn, H., Min, H., Oh, S. J., Lee, M. S., Park, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.006 · Cited by 24
Ottilie, S., Luth, M. R., Hellemann, E., Goldgof, G. M., Vigil, E., Kumar, P., Cheung, A. L., Song, M., Godinez‐Macias, K. P., Carolino, K., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03076-7 · Cited by 23
Mas-Ponte, D., McCullough, M., & Supek, F. (2022) · Clinical Science · doi:10.1042/cs20210682 · Cited by 24
Li, F., Wang, Y., Hwang, I., Jang, J.-Y., Xu, L., Deng, Z., Yu, E. Y., Cai, Y., Wu, C., Han, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37480-2 · Cited by 25
Massively parallel CRISPR off-target detection enables rapid off-target prediction model building
Tian, R., Cao, C., He, D., Dong, D., Sun, L., Liu, J., Chen, Y., Wang, Y., Huang, Z., Li, L., et al. (2023) · Med · doi:10.1016/j.medj.2023.05.005 · Cited by 25
Grillone, K., Ascrizzi, S., Cremaschi, P., Amato, J., Polerà, N., Croci, O., Rocca, R., Riillo, C., Conforti, F., Graziano, R., et al. (2024) · Blood · doi:10.1182/blood.2023021991 · Cited by 23
Self-citationHerms, A., Fernández‐Antorán, D., Alcolea, M. P., Kalogeropoulou, A., Banerjee, U., Piedrafita, G., Abby, E., Valverde-Lopez, J. A., Ferreira, I. S. D. S. R., Caseda, I., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01875-8 · Cited by 26
Novel molecular targets for the treatment of lung cancer
Rosell, R., Karachaliou, N., & Arrieta, O. G. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000590 · Cited by 24
iCSDB: an integrated database of CRISPR screens
Choi, A., Jang, I., Han, H., Kim, M., Choi, J., Lee, J. L., Cho, S., Jun, Y., Lee, C., Kim, J., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa989 · Cited by 25
Zhou, W., Li, J., Lu, X., Liu, F., An, T., Xiao, X., Kuo, Z. C., Wu, W., & He, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617289 · Cited by 23
LRR1-mediated replisome disassembly promotes DNA replication by recycling replisome components
Fan, Y., Köberlin, M. S., Ratnayeke, N., Liu, C., Deshpande, M., Gerhardt, J., & Meyer, T. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202009147 · Cited by 22
Metadata
- Authors
- Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., Ansari, R., Harper, S., Jackson, D. A., McRae, R., Pooley, R., Wilkinson, P., van der Meer, D., Dow, D., Buser-Doepner, C., Bertotti, A., Trusolino, L., Stronach, E. A., Saez-Rodriguez, J., Yusa, K., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute (GB)
- European Bioinformatics Institute (GB)
- Candiolo Cancer Institute (IT)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Kyoto University (JP)
- Corresponding author
- Yusa, Kosuke
- Garnett, Mathew J.
- ORCID
- Venue
- Nature
- Published
- 2019-04-10
- Volume
- 568
- Issue
- 7753
- Pages
- 511-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2936686072
- Cited by
- 1,338
- References
- 64
- Citations by year
- 2026: 129 · 2025: 168 · 2024: 200 · 2023: 158 · 2022: 200 · 2021: 227 · 2020: 179 · 2019: 74
- FWCI
- 56.69
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Wellcome Trust (C44943/A22536, SU2C-AACR-DT1213, 102696, 206194)
- Cancer Research UK (A22536, SU2C-AACR-DT1213, 102696, C44943/A22536)
- Associazione Italiana per la Ricerca sul Cancro (5X 1000, 21091, 20697, 18532)
- Stand Up To Cancer (SU2C-AACRDT1213)
- H2020 European Research Council (724748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- cancer cell lines, synthetic lethality, microsatellite instability, cancer dependency, genomic biomarkers, anticancer drug development
- MeSH terms
- Werner Syndrome Helicase, Synthetic Lethal Mutations, Gene Editing, Animals, Female, Humans, Neoplasm Transplantation, Neoplasms, Organ Specificity, Biomarkers, Tumor, Werner Syndrome, Reproducibility of Results, Genome, Human, Cell Line, Tumor, Mice, Microsatellite Instability, Drug Discovery, Molecular Targeted Therapy, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
